Every material Form 8-K PULSE BIOSCIENCES, INC. has filed with the SEC since October 07, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Pulse Biosciences reported interim six-month results from its PRECISE-BTN study of the nPulse Vybrance system for symptomatic benign thyroid nodules, presented at the American Thyroid Association meeting. In the interim dataset of 43 patients, 86% achieved at least 50% nodule volume reduction at six months, and no serious adverse events were reported. The results are early, cover a subset of the study's enrolled patients, and do not include financial figures.
86% of the 43 evaluated patients achieved at least 50% nodule volume reduction at six months, the primary endpoint
Median volume reduction was 72% at six months, with most reduction evident by the one-month visit
ThyPRO-39 quality of life score improved 78% from baseline; 82% of patients with baseline neck pressure or fullness reported full resolution at six months
No serious adverse events were reported; the company expects to report full six-month and 12-month data for all patients
Pulse Biosciences reported third quarter 2026 revenue of $0.4 million, up from $0.1 million a year earlier, while its GAAP net loss widened to $23.1 million from $19.4 million. The company also said it completed enrollment in its U.S. pivotal NANOPULSE-AF study and ended the quarter with $189.2 million in cash, cash equivalents, and marketable securities, after raising $95.8 million through its ATM programs.
GAAP net loss was $23.1 million, or $0.32 per share, versus $19.4 million, or $0.29 per share, a year earlier.
Cash, cash equivalents, and marketable securities totaled $189.2 million as of September 30, 2026, compared with $101.6 million on June 30, 2026.
NANOPULSE-AF pivotal study completed enrollment with 169 evaluable patients, three months ahead of the original plan.
Pulse Biosciences announced on October 14, 2026, a commercial and clinical partnership with the Clayman Thyroid Center at the Hospital for Endocrine Surgery in Tampa, Florida, and its affiliates. The center is now treating patients with the nPulse Vybrance Percutaneous Electrode System, and the two parties will collect real-world outcomes data and work on formal clinical studies of the system for benign thyroid nodules. The filing does not disclose financial terms, so the partnership's effect on Pulse Biosciences' revenue is not quantified.
Partnership announced October 14, 2026, with the Clayman Thyroid Center and its affiliates in Tampa, Florida
The center is now treating patients with the Vybrance System as part of the company's controlled market development strategy
The center is the only site in the Tampa Bay Area offering nPulse technology for symptomatic benign thyroid nodules
Collaboration covers real-world outcomes collection and formal clinical studies; the filing gives no financial terms
Pulse Biosciences said its NANOPULSE-AF pivotal study of the nPulse Cardiac Catheter System for atrial fibrillation reached its enrollment target of 164 evaluable patients across 15 clinical sites. The company said enrollment finished three months ahead of its original 9-month timeline, and primary safety and effectiveness endpoints will be assessed at 6 and 12 months after ablation, so the filing contains no financial results or guidance.
Study reached its target of 164 evaluable patients across 15 clinical sites
First patients were treated in April 2026
Enrollment finished three months ahead of the original 9-month timeline
Primary endpoints will be assessed at 6 and 12 months post-ablation
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every PULSE BIOSCIENCES, INC. filing is on SEC EDGAR ↗. 8-K briefs of other companies →